Jinfeng Xiang

Academic reputation -Medical scientist & Oncologist (GI) in Shanghai Pancreatic Cancer Institute -Medical doctor in Oncological Surgery Department of Fundan University Shanghai Cancer Center (FUSCC) - Member of European Pancreatic Club (EPC) - Member (Outstanding Young Investigator) of JSCO & FACO - Member (Outstanding Young Investigator) of CACA and CSCO - Exchange resident doctor in MSKCC Academic publication 1. Participated in 3 scientific research funds as project leader in hospital and Fudan University 2. Participated in 2 multi-center clinical trials of pancreatic cancer as Sub-PI (CSPAC-001 & CSPAC-002) 3. Members of EPC, JSCO/FACO, CSCO and the Outstanding Young Investigator of IAP 4. SCI (First author only) 1. Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC, Cancer Letters, 0304-3835, 2015-01 2. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC), International Journal of Oncology, 1019-6439, 2015-12 3. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting surgical outcomes of pancreatic ductal adenocarcinoma, Surgery, 0039-6060, 2016-08 4. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer, Cell Death Dis. 2018 Feb 23;9(3):321 5. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 >/= 1,000 U/mL，Scientific Report. 2016 5. Chinese article (First author only) 1. 2015年胰腺癌研究及诊疗前沿进展, 中国癌症志, 1007-3639, 2016-04 2. 消化系统恶性肿瘤的肿瘤免疫状态和分子分型: 描述肿瘤特征及影响临床预后及治疗的重要因素, 世界华人消化杂志, 2219-2859, 2016-09 3. 2016版国际胰腺外科研究组术后胰瘘定义和分级系统更新内容介绍和解析， 中国实用外科杂志， 2017 Vol. 37 (02): 149-152